New member of Symrise's Supervisory Board: Dr. ...
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
(Holzminden/Frankfurt) Fragrance and flavoring manufacturer Symrise
welcomes Dr. Thomas Rabe, CFO at Bertelsmann, as the newest member of
its Supervisory Board.
On April 22nd 2009 the local court of Hildesheim appointed Dr. Thomas
Rabe (43) to become a new member of the Supervisory Board of
Symrise, effective immediately. Dr. Thomas Rabe is the official
successor of Klaus Kühn, CFO at Bayer, who stepped down from
Symrise's Supervisory Board on December 31, 2008. Dr. Rabe is one of
the six members of the Supervisory Board, who are representing the
shareholders.
Dr. Rabe has been the chief financial officer at Bertelsmann since
2006. He studied business administration at the University of
Cologne, where he also completed a doctoral degree (Dr. rer. pol.) in
1995..Dr. Rabe began his career in 1989. Early on he held various
positions at the European Commission, the legal firm Forrester Norall
& Sutton, the Treuhandanstalt and an investment company. In 1998 he
was named a member of the board at the custodian bank Cedel (now
Clearstream AG). He became CFO of the RTL Group in 2000 before being
appointed CFO and head of the corporate center at Bertelsmann in
2006.
Dr. Rabe is currently also on the Supervisory Boards of the RTL Group
and Gruner & Jahr. He is married and lives in Berlin and Gütersloh.
"The Supervisory Board of Symrise AG is pleased to welcome our new
member, Dr. Thomas Rabe, who has outstanding expertise in financial
issues", says Andreas Schmid, Chairman of the Supervisory Board. As
an independent expert and member of the Audit Committee of the
Supervisory Board of Symrise AG, Dr. Rabe will advise the Symrise
Group in all financial matters.
About Symrise
Symrise is a global supplier of fragrances, flavorings and raw
materials and active ingredients for the perfume, cosmetics and food
industry.
Its sales of ¤1.32 billion in 2008 place the company among the top
four in the international flavors and fragrances market.
Headquartered in Holzminden, Germany, Symrise is represented in more
than 35 countries in Europe, Asia, the United States and South
America.
The number of patent applications the company files each year lies
significantly above the industry average, making Symrise one of the
most innovative manufacturers on the market. Used by manufacturers of
perfumes, cosmetics and foods, our products are an inseparable part
of daily life. At Symrise we combine an awareness of consumer trends
with cutting-edge technologies, focusing on innovative fashion and
lifestyle products that have additional practical value for the
consumer. Symrise - always inspiring more.
www.symrise.com
Contact:
Katja Derow,
red roses communications,
Phone: 0049-40-4696770-10,
e-mail: k.derow@redroses-pr.com
--- End of Message ---
Symrise AG
Mühlenfeldstraße 1 Holzminden Germany
WKN: SYM999; ISIN:
DE000SYM9999; Index: MDAX, TecDAX;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse, Freiverkehr
in Bayerische Börse München,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Prime Standard in Frankfurter Wertpapierbörse;
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.